Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764931 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL21753322 | 0.88 | ALDH1A1 (0.52) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL23610494 | 0.82 | KMT2A (0.49) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL8122536 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNAMAPK1MAPT | |
| SCHEMBL19095281 | 0.78 | KMT2A (0.73) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL30543496 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL13879509 | 0.76 | KMT2A (0.91) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL26037567 | 0.76 | HSD11B1 (0.49) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL26037607 | 0.75 | HSD11B1 (0.48) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4828017 | 0.74 | CCR2 (0.52) | ALDH1A1KMT2ASMN1; SMN2MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | ALDH1A1 142/4885KMT2A 1851/4885SMN1; SMN2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.